Dynamics of biosimilar uptake in emerging markets.
Hemlata ChhabraMorgane C MouslimSmita KashiramkaAnurag Singh RathorePublished in: Expert opinion on biological therapy (2022)
Implementation of pricing and procurement policies, as well as provider and patient confidence in biosimilar efficacy, are key factors in their uptake. Due to the high cost of biosimilar development, incentivizing domestic companies with the biosimilar manufacturing capability to produce these drugs will be helpful in ensuring a sustainable biosimilar market and a steady supply chain.